Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Galmed Pharmaceuticals Ltd announces FDA clearance of IND of armachol for treatment of fatty liver disorders


Tuesday, 22 Jul 2014 09:20am EDT 

Galmed Pharmaceuticals Ltd:Announces that the U.S. Food and Drug Administration, or the FDA, cleared Galmed's Investigational New Drug, or IND, application.Such clearance will permit Galmed to conduct clinical trials of its product candidate, aramchol, in the United States for the treatment of fatty liver disorders.Says in connection with the FDA's clearance of Galmed's IND application, Galmed submitted a request to the FDA for the approval of a Fast Track Designation for aramchol. 

Company Quote

8.58
-0.3 -3.38%
4:00pm EDT